Summary
Merck & Co., Inc. (MRK) has filed an amendment (8-K/A) to its original Form 8-K filed on February 1, 2019. This amendment's sole purpose is to correct a minor typographical error in previously provided supplemental financial information (Exhibit 99.2). Specifically, the global full-year 2018 sales figure for Isentress / Isentress HD was incorrectly reported as $1,410 million and has been corrected to $1,140 million. Investors should note that this is a technical correction and does not impact any other information disclosed in the original filing. The core business and financial reporting from the initial 8-K remain unchanged. The correction pertains to a single product's reported sales, which is a relatively small adjustment within Merck's overall revenue. No other financial statements or exhibits were altered by this amendment.
Key Highlights
- 1Amendment filed to correct a typographical error in a previous 8-K filing.
- 2The error was in the Global Full Year 2018 sales figure for Isentress / Isentress HD.
- 3The reported sales figure has been corrected from $1,410 million to $1,140 million.
- 4This is a minor correction and does not affect other financial information or exhibits from the original filing.
- 5The filing is an '8-K/A' indicating it's an amendment to a previously submitted Form 8-K.
- 6The amendment solely refurnishes Exhibit 99.2, which contains certain supplemental information.